Work

P-358. Long-Acting Cabotegravir and Rilpivirine in People Living with HIV and Obesity: Real-World Insights from the RELATIVITY Cohort

Year: 2026

Type: article

Abstract: Background Long-acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) is a well-established regimen for people living with HIV (PLWH), offering high efficacy and tolerability. However, data are limited for individuals with a body mass index (BMI) > 30 kg/m², which may represent a potential risk factor for virological failure. Survival curves for virological failure by baseline BMI category in patients on LAI CAB+RPV. Methods We conducted a multicenter, retro-prospective study (RELATIVITY cohort in Spain) of virologically suppressed PLWH switching to LAI CAB+RPV, with a BMI > 30. We described this population and evaluated factors associated with virological outcomes using Kaplan–Meier analysis. Results A total of 3,203 patients were included in the study: 37 (1.2%) were underweight, 879 (27.5%) had normal weight, 807 (25.2%) were overweight, and 279 (8.7%) were obese (BMI >30). The obese group was significantly older (47 vs. 44 years; p < 0.001) and had a higher proportion of women compared to the normal-weight group (22.3% vs. 14.5%; p < 0.001). Foreign nationality was also more frequent among obese individuals (33.6% vs. 27%; p = 0.028). Comorbidities increased significantly with higher BMI: hypertension (8.3% to 21.5%), diabetes (3.8% to 10.4%), dyslipidemia (17.6% to 36.2%), and non-alcoholic fatty liver disease (1.4% to 6.1%) (p < 0.001 for all comparisons). The most frequent reasons for switching were treatment simplification (25.4%) and improvement in quality of life (55.6%). Standard needles were used in 68.7% of individuals with a BMI >30. Kaplan–Meier analysis revealed no statistically significant differences in time to virological failure across BMI groups, although individuals with obesity showed a non-significant trend toward higher failure rates after 12 months. Cox regression analysis also confirmed the absence of an association. Four individuals (1.4%) in the obese group experienced virological failure, with emergent resistance mutations detected in only one case (L100I, K103N, L74M, T97A, G140S, Q148K, Q148R, E157Q). Discontinuation rates were similar across groups, including those related to local (1.8%) and systemic (1.1%) adverse events. Conclusion In real-world settings, LAI CAB+RPV appears to be a viable option for individuals with a BMI > 30 kg/m², demonstrating efficacy and safety rates comparable to those observed in other real-world cohorts. Disclosures All Authors: No reported disclosures

Source: Open Forum Infectious Diseases

DOI: 10.1093/ofid/ofaf695.576

Authors: Jesús Troya, Rafael Micán, María José Galindo, Otilia Bisbal, Lucía Romero, Miguel Torralba, Luis Buzón-Martín, Sara de la Fuente, Francisco Fanjul, Adrían Rodríguez, Alfonso Cabello, Isabel Sanjoaquin, Maria del carmen Navarro, María Aguilera, Carmen Hidalgo, Luis Enrique Morano, Clara Martínez, Inmaculada Poquet, Enrique Bernal, Ruth Caballero, Noemí Cabello, Juan Tiraboshi, María del Carmen Montero, María Jesús Vivancos, Francisco Tejerina, Guillermo Soria, Miguel Alberto de Zárraga, Mireia Cairó, Alberto Romero, Rebeca Cabo, Víctor Arenas, Maria Antonia Sepúlveda, Antonia Alcaraz, Cristina Escrich, Claudia González, Eva María Ferreira, Beatriz Valentín, Magdalena Muelas, Jara Llenas, Sara García, Juan Emilio Losa, Bárbara Alonso, José Sanz, Felix Gutiérrez, Nuria Vázquez, Juan José Corte, María Ángeles Garcinuño, Juan Carlos Gainzarain, Miriam Estébanez, Marisa Montes

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,053

OpenAlex ID: W7122408116

FWCI:

Cites:

Cited by:

Related to: